Provided by Tiger Trade Technology Pte. Ltd.

Galapagos NV

27.73
0.0000
Volume:- -
Turnover:- -
Market Cap:1.83B
PE:- -
High:27.73
Open:27.73
Low:27.73
Close:27.73
52wk High:37.78
52wk Low:25.97
Shares:65.90M
Float Shares:65.05M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):5.72
ROE:16.26%
ROA:10.65%
PB:0.48
PE(LYR):4.85

Loading ...

Company Profile

Company Name:
Galapagos NV
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.